Columbus Global

Strategic collaboration enables Life Science companies to adopt a cloud strategy

Del
Strategic collaboration between Columbus and Epista Life Science enables the conservative Pharmaceutical Industry to move their ERP system to the cloud AND stay in control of quality.

Life Science companies are historically late adopters of new technology, due to the heavily regulated nature of the industry. Patient safety and product quality are priority one, which means they must continuously prove they are in control of their IT systems. Staying in control of ERP systems has always been a challenge for Life Science companies. And today the challenge is even greater, with cloud systems forcing patches and upgrades several times per year. It’s now exponentially more demanding to maintain the validated state of your ERP system after go-live.

Columbus and Epista are leaders in digital transformation and operation of Pharma solutions via Microsoft Dynamics 365FO - both in terms of experience, insight and volume. The new strategic collaboration between these two IT consultancies enables Life Science companies to take advantage of the cloud benefits that other industries have been enjoying for a long time.

With more than 30 years in the global digitalization industry and emphasis on a regulated market, Columbus has established a stable and comprehensive foundation of operational offerings by means of current, structured services making sure that cloud-based pharma solutions will remain validated.

Epista Life Science is dedicated to continuously improving regulatory compliance. Throughout their decade of growth, they have pioneered new methods to help Life Science companies take advantage of technological advances in IT while remaining efficient, in control and in compliance.

The result of the trinity between product (Microsoft Dynamics 365FO), offerings and services (Columbus) and quality assurance and validation (Epista Life Science), enables Life Science companies to pursue a cloud strategy that will keep them efficiently in control and future-proof their business.

“In recent years, we have successfully specialized in accommodating the increasingly high demand for continuous updates. Updates that especially Cloud environments require in order to streamline processes and procedures. In addition to world-class Change Control, Release Management Processes and Automated Testing Programs, Columbus is now able to deliver - in collaboration with Epista Life Science. GxP validation services around the individual future updates of Microsoft D365FO, securing effective and efficient decision making. Therefore, we have high expectations of our for, and are very pleased about with, our the collaboration with Epista Life Science,” says Lasse Bruhn, Vice President, Customer Operations, Columbus A/S.

Klavs Esbjerg, CEO and founder of Epista Life Science states: “When Life Science companies consider a new ERP system, they naturally focus on the large and complex implementation project standing before them. In Epista’s extensive experience, we commonly see Life Science companies make a huge mistake here. All too often, they underestimate, or overlook altogether, the next phase in the system lifecycle – namely ongoing operations and maintenance. We’re excited about our collaboration with Columbus in this area, because we believe it will help us turn our client’s obstacles into real business opportunities - and finally take advantage of all the benefits that cloud ERP systems have to offer.

This strategic collaboration between Columbus and Epista will future-proof Life Science companies with ERP solutions which that can be scaled as products develop and the business grows.

Kontakter

Columbus A/S:
Vice President, Customer Operations
Lasse Bruhn
LBR@columbusglobal.com
+45 29690532


Epista Life Science A/S
CEO
Klavs Esbjerg
ke@epista.com
+45 40272313

Information om Columbus Global

Columbus Global
Columbus Global
Lautrupvang 6
2750 Ballerup

https://www.columbusglobal.com

Columbus is a global IT services and consulting company specialized in digital transformation. Our more than 1,500 digital explorers collaborate with our customers in the manufacturing, retail & distribution, and food & process industries. We advise, implement and manage business critical solutions within Strategy & Change, Customer Experience, Digital Commerce, Data & Analytics, Application Management and Cloud ERP. Headquartered in Denmark, we have offices and partners worldwide - delivering locally on a global scale

Følg pressemeddelelser fra Columbus Global

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Columbus Global

New analysis of Columbus’ financial results for Q3 2023 and new strategy; New Heights4.12.2023 14:22:29 CET | Nyhed

The stock analysis firm, Aktieinfo, has just published an analysis of Columbus’ results for Q3 2023 and the newly published strategy - New Heights. The analysis concludes, among other things, that: "After ten consecutive quarters of growth and maintaining guidance for 2023 with organic growth expected to be between 8-12% and an EBITDA margin of 7.4-9.0%, Columbus concludes the strategic plan Focus23. All goals have been achieved. Now, new ambitious yet achievable goals are set for the period 2024-26, anticipating an annual average organic growth of 10% and a significant improvement in the EBITDA margin to 15% by 2026. Columbus is thus taking a step towards 'New Heights' for revenue, earnings, and stock prices." The analysis can we found here (in Danish): https://ir.columbusglobal.com/static-files/7dc8b8dd-b686-4a70-8dc9-5b93f513aaa5

Strong Q3 Interim Report, new ambitious growth targets for 2024-2026 and new focus on Life Science15.11.2023 09:18:19 CET | Pressemeddelelse

In the third quarter of 2023, Columbus once again delivered impressive organic top-line growth of 15% (excluding acquisitions and currency), and the increase in operating profit (EBITDA) was as much as 28%. Columbus has created a solid foundation for the upcoming strategy period – New Heights – which in particular will focus on boosting profitability with an EBITDA margin of 15% by the end of 2026. Columbus expects 10% compounded annual growth in 2024 – 2026.

New analysis of Columbus’ financial result for Q2 2023 published by Aktieinfo31.8.2023 12:16:10 CEST | Pressemeddelelse

The analysis concludes, among other things, that: Columbus delivers what is promised. Growth adjusted for acquisition and currency was achieved with 16% in the second quarter (19% adjusted for currency and including acquisitions) and 14% in the first half of the year. In the second quarter, Columbus managed to invoice 70% of the consultants' hours. This testifies increased efficiency, which is one of the goals of the Focus23 strategy. With the execution of the Focus23 strategy, Columbus appears stringent and focused on servicing the core customer group. The analysis can we found here (in Danish): https://ir.columbusglobal.com/static-files/96127943-4e58-4e34-97be-3790aa0f0a06

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
HiddenA line styled icon from Orion Icon Library.Eye